KIYATEC enrolls first patients with solid tumors in clinical study of its EV3D drug r
KIYATEC, Inc. today announced the enrollment of the first patients in a U.S. clinical study of its Ex Vivo 3D drug response assay across several difficult-to-treat solid tumors.